Literature DB >> 9499041

Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.

G Veres1, U Junker, J Baker, C Barske, C Kalfoglou, H Ilves, S Escaich, H Kaneshima, E Böhnlein.   

Abstract

The antiviral activities of intracellularly expressed antisense RNAs complementary to the human immunodeficiency virus type 1 (HIV-1) pol, vif, and env genes and the 3' long terminal repeat (LTR) sequence were evaluated in this comparative study. Retroviral vectors expressing the antisense RNAs as part of the Moloney murine leukemia virus LTR promoter-directed retroviral transcript were constructed. The CD4+ T-cell line CEM-SS was transduced with retroviral constructs, and Northern blot analyses showed high steady-state antisense RNA expression levels. The most efficient inhibition of HIV-1 replication was observed with the env antisense RNA, followed by the pol complementary sequence, leading to 2- to 3-log10 reductions in p24 antigen production even at high inoculation doses (4 x 10(4) 50% tissue culture infective doses) of the HIV-1 strain HXB3. The strong antiviral effect correlated with a reduction of HIV-1 steady-state RNA levels, and with intracellular Tat protein production, suggesting that antisense transcripts act at an early step of HIV-1 replication. A lower steady-state antisense RNA level was detected in transduced primary CD4+ lymphocytes than in CEM-SS cells. Nevertheless, replication of the HIV-1 JR-CSF isolate was reduced with both the pol and env antisense RNA. Intracellularly expressed antisense sequences demonstrated more pronounced antiviral efficacy than the transdominant RevM10 protein, making these antisense RNAs a promising gene therapy strategy for HIV-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499041      PMCID: PMC109480          DOI: 10.1128/JVI.72.3.1894-1901.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev.

Authors:  G J Nabel; B A Fox; L Post; C B Thompson; C Woffendin
Journal:  Hum Gene Ther       Date:  1994-01       Impact factor: 5.695

2.  Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.

Authors:  S W Lee; H F Gallardo; E Gilboa; C Smith
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.

Authors:  C Zhou; I C Bahner; G P Larson; J A Zaia; J J Rossi; E B Kohn
Journal:  Gene       Date:  1994-11-04       Impact factor: 3.688

4.  Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer.

Authors:  S P Forestell; J S Dando; J Chen; P de Vries; E Böhnlein; R J Rigg
Journal:  Gene Ther       Date:  1997-06       Impact factor: 5.250

5.  RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells.

Authors:  S Escaich; C Kalfoglou; I Plavec; S Kaushal; J D Mosca; E Böhnlein
Journal:  Hum Gene Ther       Date:  1995-05       Impact factor: 5.695

6.  Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes.

Authors:  T VandenDriessche; M K Chuah; L Chiang; H K Chang; B Ensoli; R A Morgan
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Detection of intracellular HIV-1 Rev protein by flow cytometry.

Authors:  R J Rigg; J S Dando; S Escaich; I Plavec; E Böhnlein
Journal:  J Immunol Methods       Date:  1995-12-27       Impact factor: 2.303

8.  Quantitative evaluation of intracellular sense: antisense RNA hybrid duplexes.

Authors:  S Wang; B J Dolnick
Journal:  Nucleic Acids Res       Date:  1993-09-11       Impact factor: 16.971

9.  Inhibition of HIV-1 multiplication in a human CD4+ lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and Rev response element(s).

Authors:  H Cohli; B Fan; R L Joshi; A Ramezani; X Li; S Joshi
Journal:  Antisense Res Dev       Date:  1994

10.  Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients.

Authors:  C Woffendin; U Ranga; Z Yang; L Xu; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

View more
  7 in total

1.  Gene therapy for HIV infections: Intracellular immunization.

Authors:  A Piché
Journal:  Can J Infect Dis       Date:  1999-07

Review 2.  Engineering T Cells to Functionally Cure HIV-1 Infection.

Authors:  Rachel S Leibman; James L Riley
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

3.  Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference.

Authors:  Wee-Sung Park; Naoko Miyano-Kurosaki; Masaaki Hayafune; Emiko Nakajima; Tetsuo Matsuzaki; Fumiyuki Shimada; Hiroshi Takaku
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

4.  Co-packaging of sense and antisense RNAs: a novel strategy for blocking HIV-1 replication.

Authors:  S F Ding; J Noronha; S Joshi
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

5.  Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance.

Authors:  Xiaobin Lu; Qiao Yu; Gwendolyn K Binder; Ziping Chen; Tatiana Slepushkina; John Rossi; Boro Dropulic
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 6.  Genetic therapies against HIV.

Authors:  John J Rossi; Carl H June; Donald B Kohn
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

Review 7.  Molecular strategies to inhibit HIV-1 replication.

Authors:  Morten Hjuler Nielsen; Finn Skou Pedersen; Jørgen Kjems
Journal:  Retrovirology       Date:  2005-02-16       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.